Back to list

Clinical trial of alvelestat in alpha-1 antitrypsin patients

University of North Carolina at Chapel Hill


Description

The purpose of the study is to test how a new drug called Alvelestat affects the signs of lung damage caused by Alpha-1 antitrypsin deficiency (AATD). AATD is a rare genetic condition that can cause Chronic Obstructive Pulmonary Disease (COPD.)


Keywords:

Genetics, Lungs


Category:

Drug or Biologic
Phase:2

Qualifications

 


Age
25 - 80 years


Gender
Any


Study Population

Individuals age 25-80 with alpha-1 antitrypsin


Investigator

Brad Drummond
Associate Professor
Medicine-Pulmonary

For questions, contact:

Andrea McDaniel-Harper
harper41@email.unc.edu
(984) 974-2969
Visit Website

Recruitment Period End

November 15, 2021

Location

Primary Location
UNC Meadowmont Pulmonary Research Center
300 Meadowmont Village Cir #203, Chapel Hill, NC 27517, USA

Study Qualifications

Gender Any

Age Range 25 - 80 years

Participant qualification(s) -Age 25 to 80 -Confirmed diagnosis of alpha-1 antitrypsin deficiency -Male or female

Not eligible if: - Pregnancy or plan to become pregnant - History of cirrhosis, hepatitis or HIV - History of heart failure

Number of Visits

    » 14 In person visit(s)

    1-2 Screening, 1 eye exam, 1 CAT scan, 1 randomization, 9 follow-up visits

    » 3 Remote visit(s)

    3 Phone visits

Participation Period

Up to 6 months (3 months of medication)

Compensation

$50-$100 per study visit. Total compensation $830

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.